Summit Corporation plc Stock London S.E.
Equities
GB00B02T3K57
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- GBX | - |
|
Jul. 01 | Summit Therapeutics Inc.(NasdaqGM:SMMT) added to Russell Small Cap Comp Value Index | CI |
Jul. 01 | Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell Microcap Growth Index | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.62B 6B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 11.86% |
Latest transcript on Summit Corporation plc
Managers | Title | Age | Since |
---|---|---|---|
Mahkam Zanganeh
CEO | Chief Executive Officer | 52 | 20-11-10 |
Robert Duggan
CEO | Chief Executive Officer | 79 | 19-11-30 |
Director of Finance/CFO | 46 | 19-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Duggan
CEO | Chief Executive Officer | 79 | 19-11-30 |
Robert Booth
BRD | Director/Board Member | 70 | 22-09-27 |
Director of Finance/CFO | 46 | 19-11-30 |
1st Jan change | Capi. | |
---|---|---|
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |